[1]中国免疫学会神经免疫学分会，中华医学会神经病学分会神经免疫学组，中国医师协会神经内科分会神经免疫专业委员会.中国视神经脊髓炎谱系疾病诊断与治疗指南[J].中国神经免疫学和神经病学杂志, 2016, 23(3):155-166
[2]Hardy T A, Reddel S W, Barnett M H, et al.Atypical inflammatory demyelinating syndromes of the CNS[J].Lancet Neurol, 2016, 15(9):967-981
[3]Lennon V A, Wingerchuk D M, Kryzer T J, et al.A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis[J].Lancet, 2004, 364(9451):2106-2112
[4]Oji S, Nomura K.Immunoadsorption in neurological disorders[J].Transfus Apher Sci, 2017, 56(5):671-676
[5]Ratelade J, Verkman A S.Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies[J].Int J Biochem Cell Biol, 2012, 44(9):1519-1530
[6]Jacob A, Mckeon A, Nakashima I, et al.Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders[J].J Neurol Neurosurg Psychiatry, 2013, 84(8):922-930
[7]Klingel R, Heibges A, Fassbender C.Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption[J].Atheroscler Suppl, 2013, 14(1):161-165
[8]Isobe N, Yonekawa T, Matsushita T, et al.Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica[J].Mult Scler, 2012, 18(11):1541-1551
[9]Yasuda T, Mikami T, Kawase Y.Efficacy of Tryptophan Immunoadsorption Plasmapheresis for Neuromyelitis Optica in Two Cases[J].Ther Apher Dial, 2015, 19(4):411-412
[10]Koziolek M J, Tampe D, Bahr M, et al.Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis[J]. J Neuroinflammation, 2012, 9:80.[J].J Neuroinflammation, 2012, 9:80-80
[11]Schimrigk S, Faiss J, Kohler W, et al.Escalation Therapy of Steroid Refractory Multiple Sclerosis Relapse with Tryptophan Immunoadsorption - Observational Multicenter Study with 147 Patients[J].Eur Neurol, 2016, 75(5-6):300-306
[12]Kobayashi M, Nanri K, Taguchi T, et al.Immunoadsorption therapy for neuromyelitis optica spectrum disorders long after the acute phase[J].J Clin Apher, 2015, 30(1):43-45
[13]Kleiter I, Gahlen A, Borisow N, et al.Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses[J].Ann Neurol, 2016, 79(2):206-216
[14]Kleiter I, Gahlen A, Borisow N, et al.Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions[J].Neurol Neuroimmunol Neuroinflamm, 2018, 5(6):e504-e504
[15]Faissner S, Nikolayczik J, Chan A, et al.Immunoadsorption in patients with neuromyelitis optica spectrum disorder[J].Ther Adv Neurol Disord, 2016, 9(4):281-286
[16]Fujiwara S, Manabe Y, Morihara R, et al.Two Cases of Very-Late-Onset Neuromyelitis Optica Spectrum Disorder (NMOSD) in Patients over the Age of 80[J].Case Rep Neurol, 2020, 12(1):13-17
[17]Collongues N, Marignier R, Jacob A, et al.Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset[J].Mult Scler, 2014, 20(8):1086-1094
[18]Borisow N, Kleiter I, Gahlen A, et al.Influence of female sex and fertile age on neuromyelitis optica spectrum disorders[J].Mult Scler, 2017, 23(8):1092-1103
[19]Shimizu Y, Fujihara K, Ohashi T, et al.Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder[J].Mult Scler, 2016, 22(11):1413-1420
[20]Blais L, Beauchesne M F, Lemiere C, et al.High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations[J].J Allergy Clin Immunol, 2009, 124(6):1229-1234
[21]Gur C, Diav-Citrin O, Shechtman S, et al.Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study[J].Reprod Toxicol, 2004, 18(1):93-101
[22]Hoffmann F, Kraft A, Heigl F, et al.Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica: therapy option for acute relapses during pregnancy and breastfeeding][J].Nervenarzt, 2015, 86(2):179-186
[23]Hoffmann F, Kraft A, Heigl F, et al.Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica[J].Ther Adv Neurol Disord, 2018, 11:1756286418774973-1756286418774973
[24]Saadoun S, Waters P, Bell B A, et al.Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice[J].Brain, 2010, 133(Pt 2):349-361
[25]Barros P O, Cassano T, Hygino J, et al.Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase[J].Clin Exp Immunol, 2016, 183(3):480-489
[26]Nishimura H, Enokida H, Sakamoto T, et al.Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level[J].J Artif Organs, 2018, 21(3):378-382
[27]Ako S, Kaneko Y, Higuchi M, et al.Crow-Fukase syndrome--immunoadsorption plasmapheresis effectively lowers elevated interleukin-6 concentration[J].Nephrol Dial Transplant, 1999, 14(2):419-422
[28]Sellner J, Boggild M, Clanet M, et al.EFNS guidelines on diagnosis and management of neuromyelitis optica[J].Eur J Neurol, 2010, 17(8):1019-1032
[29]Kumawat B L, Choudhary R, Sharma C M, et al.Plasma Exchange as a First Line Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorders[J].Ann Indian Acad Neurol, 2019, 22(4):389-394
[30]Lipphardt M, Muhlhausen J, Kitze B, et al.Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica[J].J Clin Apher, 2019, 34(4):381-391
[31]Kleiter I, Gahlen A, Borisow N, et al.Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions[J].Neurol Neuroimmunol Neuroinflamm, 2018, 5(6):e504-
[32]Koessler J, Kobsar A, Kuhn S, et al.The effect of immunoadsorption with the Immusorba TR-350 column on coagulation compared to plasma exchange[J].Vox Sang, 2015, 108(1):46-51
[33]Galldiks N, Dohmen C, Neveling M, et al.Selective Immune Adsorption Treatment of Severe Guillain Barré Syndrome in the Intensive Care Unit[J].Neurocritical Care, 2009, 11(3):317-321
[34]Heigl F, Hettich R, Arendt R, et al.Immunoadsorption in steroid-refractory multiple sclerosis: Clinical experience in 60 patients[J].Atherosclerosis Supplements, 2013, 14(1):167-173
[35]Padmanabhan A, Connelly-Smith L, Aqui N, et al.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue[J].J Clin Apher, 2019, 34(3):171-354
